Lucius Partners — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

Adaptin BIOadaptinbio.comOTC: APTNFeb 2025

Adapt Biotechnologies develops the BRiTE platform, a bispecific antibody technology designed to treat brain tumors and intracerebral malignancies by activating T cells to target and destroy glioma cells.

BiotechDeep TechHealthtechMedical DevicesCharlotte, US

Michael J. Roberts(Chief Executive Officer and Director)inL. Arthur Hewitt(Chief Development Officer)Simon Pedder(Executive Chairman)Timothy L. Maness(Chief Financial Officer)

BoardAnthony Zook(Director)J. Nick Riehle(Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.